Full Press Release Details
Nurix Therapeutics Announces Initiation of Phase 1b Expansion Cohorts in Ongoing Phase 1 Trial of NX-2127.
NRIX
Nurix Therapeutics Announces Initiation of Phase 1b Expansion Cohorts in Ongoing Phase 1 Trial of NX-2127
Key Takeaway: Nurix Therapeutics Announces Initiation of Phase 1b Expansion Cohorts in Ongoing Phase 1 Trial of NX-2127
Price reaction · baseline $10.19 (2022-05-25 close) · hit after-hours · clean, no other NRIX news in the window
day 0 close · peak
-22.7%
day 1
-11.5%
day 3
-6.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma